Biomarker discovery in progressive supranuclear palsy from human cerebrospinal fluid
Biomarker candidate proteins ATP6AP2, NEFM, and CHI3L1 were identified as key differentiators of PSP from the other groups. This study represents the first large-scale use of mass spectrometry-based proteome analysis to identify cerebrospinal fluid (CSF) biomarkers specific to progressive supranuclear palsy (PSP) that can differentiate it from Parkinson's disease (PD) and healthy controls. Our findings lay a crucial foundation for the development and validation of reliable biomarkers, which will enhance diagnostic accuracy and facilitate early detection of PSP.
Authors
- Ted M. Dawson (ORCID: https://orcid.org/0000-0002-6459-0893)
- Thomas Francis Tropea (ORCID: https://orcid.org/0000-0003-0766-1496)
- Yura Jang (ORCID: https://orcid.org/0000-0002-1338-4686)
- Alexander Pantelyat (ORCID: https://orcid.org/0000-0002-6427-7485)
- Liana S. Rosenthal (ORCID: https://orcid.org/0000-0001-5140-3967)
- Alice Chen‐Plotkin (ORCID: https://orcid.org/0000-0002-3387-2038)
- Chan Hyun Na (ORCID: https://orcid.org/0000-0002-3622-2938)
- Anna J. Hall
- Zhen Zhang (ORCID: https://orcid.org/0000-0001-8446-1450)
- Sungtaek Oh (ORCID: https://orcid.org/0000-0002-3786-6372)
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
Publication Details
- Journal
- Clinical Proteomics
- Published
- 2024-09-28
- DOI
- https://doi.org/10.1186/s12014-024-09507-3
- Citations
- 5
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.85
Funders
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke